Cargando…

Effects of Bcl-2/Bcl-x(L) Inhibitors on Pulmonary Artery Smooth Muscle Cells

Pulmonary arterial hypertension (PAH) is a fatal disease without satisfactory therapeutic options. By the time patients are diagnosed with this disease, the remodeling of pulmonary arteries has already developed due to the abnormal growth of pulmonary vascular cells. Therefore, agents that reduce ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rybka, Vladyslava, Suzuki, Yuichiro J., Shults, Nataliia V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262274/ https://www.ncbi.nlm.nih.gov/pubmed/30373097 http://dx.doi.org/10.3390/antiox7110150

Ejemplares similares

Ultrastructural Changes of the Right Ventricular Myocytes in Pulmonary Arterial Hypertension
por: Shults, Nataliia V., et al.
Publicado: (2019)

Major vault protein in cardiac and smooth muscle
por: Shults, Nataliia V., et al.
Publicado: (2016)

Transmission Electron Microscopy Study of Mitochondria in Aging Brain Synapses
por: Rybka, Vladyslava, et al.
Publicado: (2019)

Radiosensitization by a novel Bcl-2 and Bcl-X(L) inhibitor S44563 in small-cell lung cancer
por: Loriot, Y, et al.
Publicado: (2014)

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2021)

Bcl-2 and Bcl-x(L) Suppress Glucose Signaling in Pancreatic β-Cells
por: Luciani, Dan S., et al.
Publicado: (2013)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

The Structural Biology of Bcl-x(L)
por: Lee, Erinna F., et al.
Publicado: (2019)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Apoptosis-based therapy to treat pulmonary arterial hypertension
por: Suzuki, Yuichiro J., et al.
Publicado: (2016)

PROTACs are effective in addressing the platelet toxicity associated with BCL-X(L) inhibitors
por: Zhang, Peiyi, et al.
Publicado: (2020)

Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2022)

Characterization of the signal that directs Bcl-x(L), but not Bcl-2, to the mitochondrial outer membrane
por: Kaufmann, Thomas, et al.
Publicado: (2003)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer
por: Magouliotis, Dimitrios E., et al.
Publicado: (2022)

Nutritional Regulators of Bcl-xL in the Brain
por: Park, Han-A, et al.
Publicado: (2018)

Smooth Muscle-Specific BCL6+/− Knockout Abrogates Sex Bias in Chronic Hypoxia-Induced Pulmonary Arterial Hypertension in Mice
por: Yang, Yang-Ming, et al.
Publicado: (2018)

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage
por: Seng, NS, et al.
Publicado: (2016)

Nrz but not zBcl-xL antagonizes Bcl-wav pro-apoptotic activity in zebrafish
por: Prudent, Julien, et al.
Publicado: (2014)

Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer
por: Alibek, Kenneth, et al.
Publicado: (2014)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Lv, Dongwen, et al.
Publicado: (2021)

Bcl-x(L) is an oncogenic driver in colorectal cancer
por: Scherr, Anna-Lena, et al.
Publicado: (2016)

Bcl-xL as a Modulator of Senescence and Aging
por: Mas-Bargues, Cristina, et al.
Publicado: (2021)

Bcl-xL: A Focus on Melanoma Pathobiology
por: Lucianò, Anna Maria, et al.
Publicado: (2021)

Involvement of Bcl-xL in Neuronal Function and Development
por: Bas, Julie, et al.
Publicado: (2021)

The Role of Bcl-xL Protein in Viral Infections
por: Wyżewski, Zbigniew, et al.
Publicado: (2021)

Roles and Regulation of BCL-xL in Hematological Malignancies
por: Morales-Martínez, Mario, et al.
Publicado: (2022)

Advances in Bcl-xL Research 2.0
por: Kervadec, Joann, et al.
Publicado: (2023)

Influence of Bcl-1 gene polymorphism of glucocortucoid receptor on phenotypic expressions of bronchial asthma
por: Kmyta, Vladyslava, et al.
Publicado: (2015)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo
por: Bai, Longchuan, et al.
Publicado: (2014)

COVID-19 patients may become predisposed to pulmonary arterial hypertension
por: Suzuki, Yuichiro J., et al.
Publicado: (2021)

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
por: Li, Ji-Yu, et al.
Publicado: (2012)

Targeting Bcl-2/Bcl-X(L) Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
por: Némati, Fariba, et al.
Publicado: (2014)

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
por: Zhang, Yiru, et al.
Publicado: (2018)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Rational design of Harakiri (HRK)-derived constrained peptides as BCL-x(L) inhibitors
por: Zhang, Peiyu, et al.
Publicado: (2023)

Effects of Cardiolipin on the Conformational Dynamics of Membrane-Anchored Bcl-xL
por: Tyagi, Vivek, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qs3jo7bh7rdtqt3ef1kd85dj47